EPIAXIS THERAPEUTICS ANNOUNCES SEARCH FOR STRATEGIC PARTNERS FOR LEADERSHIP IN EPIGENETIC CONTROL OF METASTATIC CANCER
EpiAxis has appointed The Sage Group to lead the partnering program for its peptide candidates which modulate the epigenetic control of metastatic cancer. SYDNEY, AUSTRALIA, August 12, 2019 /EINPresswire.com/ -- Following a strategic review of its clinical and...read more
EpiAxis Therapeutics, a University of Canberra spin out company, has expanded its clinical trial program to include two additional recruitment centres for its Phase 1b metastatic breast cancer program. Those centres are open for patient recruitment at the Southern...read more
EpiAxis Phase 1 FPI News Releaseread more
There is currently no therapy to fight recurrent, metastatic breast cancer, which is the major source of death in women with breast cancer. Furthermore, current first-line treatments have extensive side-effects.We are determined to fix that.
Professor Sudha Rao
Founder & Director at EpiAxis Therapeutics